Загрузка...
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
T cells expressing a CD19-specific chimeric antigen receptor (CAR19) are demonstrating remarkable efficacy in hematologic malignancies. Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively treated with cytokine blockade using the antibodies, Si...
Сохранить в:
| Опубликовано в: : | J Immunol Methods |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490247/ https://ncbi.nlm.nih.gov/pubmed/27049586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jim.2016.03.005 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|